スタチン系薬剤、
肝機能不全・急性腎不全・心筋症・白内障リスクと関連

Published 20 May 2010, doi:10.1136/bmj.c2197
Cite this as: BMJ 2010;340:c2197

Research
Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database

Julia Hippisley-Cox, professor of clinical epidemiology and general practice, Carol Coupland, associate professor in medical statistics

1 Division of Primary Care, University Park, Nottingham NG2 7RD

Correspondence to: J Hippisley-Cox julia.hippisley-cox@ntlworld.com

文献：Hippisley-Cox J et al. Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database. BMJ. 2010;340:c2197

2004692名（30-84歳）を対象に、集団ベースの前向きコホート研究にてスタチン系薬剤の適応外効果を調査。スタチン系薬剤は、食道癌リスクの低下および肝機能不全、急性腎不全、心筋症、白内障リスクの上昇と関連した。著者らはリスクを個別に明確化し、高リスク患者を厳重にモニタリングできるよう、さらなる研究が必要と指摘している。

Objective To quantify the unintended effects of statins according to type, dose, and duration of use.

Design Prospective open cohort study using routinely collected data.

Setting 368 general practices in England and Wales supplying data to the QResearch database.

Participants 2004692 patients aged 30-84 years of whom 225 922 (10.7%) were new users of statins: 159 790 (70.7%) were prescribed simvastatin, 50 328 (22.3%) atorvastatin, 8103 (3.6%) pravastatin, 4497 (1.9%) rosuvastatin, and 3204 (1.4%) fluvastatin.

Methods Cox proportional hazards models were used to estimate effects of statin type, dose, and duration of use. The number needed to treat (NNT) or number needed to harm (NNH) was calculated and numbers of additional or fewer cases estimated for 10 000 treated patients.

Main outcome measure First recorded occurrence of cardiovascular disease, moderate or serious myopathic events, moderate or serious liver dysfunction, acute renal failure, venous thromboembolism, Parkinson’s disease, dementia, rheumatoid arthritis, cataract, osteoporotic fracture, gastric cancer, oesophageal cancer, colon cancer, lung cancer, melanoma, renal cancer, breast cancer, or prostate cancer.

Results Individual statins were not significantly associated with risk of Parkinson’s disease, rheumatoid arthritis, venous thromboembolism, dementia, osteoporotic fracture, gastric cancer, colon cancer, lung cancer, melanoma, renal cancer, breast cancer, or prostate cancer. 　Statin use was associated with decreased risks of oesophageal cancer but increased risks of moderate or serious liver dysfunction, acute renal failure, moderate or serious myopathy, and cataract. Adverse effects were similar across statin types for each outcome except liver dysfunction where risks were highest for fluvastatin.
　 A dose-response effect was apparent for acute renal failure and liver dysfunction. All increased risks persisted during treatment and were highest in the first year. After stopping treatment the risk of cataract returned to normal within a year in men and women.
　 Risk of oesophageal cancer returned to normal within a year in women and within 1-3 years in men.
　Risk of acute renal failure returned to normal within 1-3 years in men and women, and liver dysfunction within 1-3 years in women and from three years in men.
　 Based on the 20% threshold for cardiovascular risk, for women the NNT with any statin to prevent one case of cardiovascular disease over five years was 37 (95% confidence interval 27 to 64) and for oesophageal cancer was 1266 (850 to 3460) and for men the respective values were 33 (24 to 57) and 1082 (711 to 2807).
　 In women the NNH for an additional case of acute renal failure over five years was 434 (284 to 783), of moderate or severe myopathy was 259 (186 to 375), of moderate or severe liver dysfunction was 136 (109 to 175), and of cataract was 33 (28 to 38). Overall, the NNHs and NNTs for men were similar to those for women, except for myopathy where the NNH was 91 (74 to 112).

Conclusions Claims of unintended benefits of statins, except for oesophageal cancer, remain unsubstantiated, although potential adverse effects at population level were confirmed and quantified. Further studies are needed to develop utilities to individualise the risks so that patients at highest risk of adverse events can be monitored closely.